Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LTA
REST API REST API
Homo sapiens
LTA is differentially expressed in 181 experiments: 59 organism parts: blood, tonsil, ... (57 more);, 126 disease states: normal, lung adenocarcinoma, ... (124 more);, 59 cell types 214 cell lines 30 compound treatments and 71 other conditions.
Synonyms LT, TNFB, TNFSF1
Orthologs tnfb (Danio rerio)   tnfa (Danio rerio)   TNFB_BOVIN (Bos taurus)   Lta (Mus musculus)   Lta (Rattus norvegicus)   NP_001107150.1 (Xenopus laevis)   TNFB_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term humoral immune response, extracellular space, membrane, tumor necrosis factor receptor binding, extracellular region, receptor binding, cell-cell signaling, response to hypoxia, cytokine activity, positive regulation of apoptosis, defense response to Gram-positive bacterium, response to nutrient, induction of apoptosis, response to lipopolysaccharide, immune response, response to drug, signal transduction, negative regulation of fibroblast proliferation, positive regulation of chronic inflammatory response to antigenic stimulus, positive regulation of humoral immune response mediated by circulating immunoglobulin, lymph node development, positive regulation of interferon-gamma production, negative regulation of growth of symbiont in host
InterPro Term TNF_family, TNF_beta, TNF_a/b/c
Gene-Disease Assocation PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO, LEPROSY, SUSCEPTIBILITY TO, 4; LPRS4
UniProt Accession Q6WQV6, P01374, Q5STV3, Q45NE9, E7ET53
Search EB-eye ENSG00000226979
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-MEXP-1251, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-4525, E-GEOD-1880, E-GEOD-22639, E-GEOD-2450, E-GEOD-24147, ... (21 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-20081
Raji
2
E-MTAB-37, E-GEOD-96
MCF7
1
E-MTAB-37
SW403
1
E-MTAB-37
sk-n-mc cell line, lentivirus treated
1
E-MTAB-62
sk-n-mc cell line; lentivirus treated
1
E-MTAB-62
208 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-360, E-GEOD-20677, ... (32 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-22373, E-GEOD-11755
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-3982, E-GEOD-22373, E-GEOD-360
mononuclear cell
1
E-GEOD-6053
dendritic cell
1
E-GEOD-360
T-ALL
1
E-GEOD-19069
53 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2069, E-TABM-15, E-GEOD-22148, ... (33 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
acute promyelocytic leukemia
2
E-GEOD-1729, E-GEOD-995
nephrosclerosis
1
E-GEOD-20602
glioblastoma
1
E-MTAB-62
high-grade prostatic intraepithelial neoplasia
1
E-MEXP-1243
acute monoblastic and monocytic leukemia
1
E-MTAB-62
120 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-TABM-782, E-GEOD-4748, E-GEOD-3720, ... (18 experiments)

Factor Value U/D Experiments
none
1
8
E-MEXP-1601, E-GEOD-2706, E-GEOD-412, E-GEOD-7307, E-TABM-868, ... (9 experiments)
lipopolysaccharide
3
E-GEOD-4748, E-TABM-868, E-MEXP-1958
saline
1
E-GEOD-3026
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
no estradiol
1
E-GEOD-20081
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725

Clinical info
studied in E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-1751

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-108, E-GEOD-6431

Genotype
studied in E-TABM-1029, E-TABM-321, E-GEOD-20115, E-TABM-868, E-TABM-601 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-MEXP-1446 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-MEXP-1648, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980, E-GEOD-17400

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1460 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-147

Processing time: 0.383 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM